Vical counts DNA as its main ally in tackling disease. The biopharmaceutical company researches and develops vaccines based on its DNA delivery technology, which uses portions of the genetic code of a pathogen to induce an immune response. Vical has a number of drug candidates in its pipeline that it is developing independently and through corporate and government collaborations. Its pipeline is focused on infectious disease, cancer immunotherapies, and cardiovascular disease. Vical's lead candidate, being independently-developed, is Allovectin-7, an immunotherapy for metastatic melanoma (skin cancer).